Advanced Search


Study ID Status Title Patient Level Data
112595 Completed Impact on nasopharyngeal carriage, acute otitis media, immunogenicity and safety of GSK Biologicals’ pneumococcal conjugate vaccine 1024850A Study Listed on
112597 Completed Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
112598 Completed Adherence of patients taking 5ARI vs 5ARI + alpha blocker combination therapy in Enlarged Prostate
112599 Completed Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
112604 Completed Comparison of Healthcare Utilization and Costs in Patients with Asthma who Fluticasone/Salmeterol Inhalation Powder versus other Inhaled Corticosteroid(s) in Typical Clinical Practice Using Health Insurance Claims Data.
112605 Completed Outcomes for Medicare asthma patients taking fluticasone propionate/salmeterol xinafoate combination versus Inhaled Corticosteroids or other combination therapy
112606 Completed Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit
112607 Completed Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients
112608 Completed Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects that Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population
112609 Completed Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate–Salmeterol Combination Versus Other Maintenance Therapies
112611 Completed Prescription Patterns, Resource Utilization & Costs - Add-on Therapy with Anti Dipeptidyl Peptidase-IVs vs rosiglitazone
112640 Completed Immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ pneumococcal vaccine GSK1024850A following primary and booster vaccination of healthy Japanese children Study Listed on
112646 Completed Outcomes and Costs Associated with initiating Maintenance Treatment with Fluticasone Propionate 250mcg/Salmeterol xinafoate 50mcg Combination (FSC) Versus Anticholinergics including Tiotropium (TIO) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
112648 Completed An open-label, randomized, single sequence, two period study to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of GSK962040 in healthy volunteers Study Listed on
112657 Completed A double-blind, randomized, placebo controlled, dose escalation, multi-centerphase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20antibody, in patients with active rheumatoid arthritis who have previously failedone or more disease modifying anti-rheumatic drugs
112662 Completed Immunogenicity and safety study of GSK Biologicals’ influenza vaccine GSK2186877A in elderly adults. Study Listed on
112668 Completed A Double-Blind, Parallel, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects Study Listed on
112670 Completed A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III congestive heart failure Study Listed on
112673 Completed Safety and immunogenicity of GlaxoSmithKline Biologicals’ herpes zoster vaccine 1437173A in adult HIV-infected subjects Study Listed on
112676 Terminated Double blind, double-dummy, randomised, placebo controlled study to evaluate the effect of single doses of drug A (lamotrigine) and drug B (vofopitant) alone and in combination on resting motor threshold in healthy subjects Study Listed on
112677 Completed Cervarix long-term safety surveillance using the PGRx information system (PGRx study)
112679 Completed Immunogenicity and safety of GSK Biologicals’ IPV (Poliorix™) in infants Study Listed on
112680 Completed A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects with Solid Tumors
112682 Completed Long-term persistence of hepatitis B antibodies and immune response to a hepatitis B vaccine challenge in 12-13 year old adolescents, vaccinated in infancy with GlaxoSmithKline (GSK) Biologicals’ HBV vaccine (Engerix™-B) Study Listed on
112683 Completed An open-label study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis Vaccine Poliorix administered as a booster dose at 18-24 months of age in healthy toddlers in China. Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.